Airship Announces Finalists for the 2024 Altitude Awards
Mobile-first customer experience company Airship today announced the finalists for its 2024 Altitude Awards, recognizing brands that have created memorable digital experiences for their customers resulting in standout mobile-first value creation.
The awards celebrate outstanding achievements in customer experience across four distinct categories: acquisition, activation, value impact and unified experience.
“Over the past 15 years, Airship has equipped brands with the solutions they need to leverage the latest digital innovations in today’s mobile-driven world," said Brett Caine, CEO of Airship. "With consumer expectations at an all-time high, our customers understand this better than anyone. This year’s Altitude Awards finalists have set a new standard, delivering the seamless and connected experiences that customers expect across digital channels.”
Representing various regions across Europe, Africa, Asia and the U.S., the finalists for the 2024 Altitude Awards are:
Acquisition: Brands with exceptional strategies to drive app downloads or website visits.
- bol for “Price Alert Push as Acquisition Strategy”
- Leroy Merlin for “Conquest of New App Users”
- RHB Banking Group for “Automated Acquisition for RHB Current and Savings Account”
Activation: Brands that excel in onboarding new app users or website customers, driving ongoing engagement, opt-ins and registrations.
- Air France-KLM for “Mobile App Opt-in Game for the 2024 Olympic Games”
- Libon for “The Retrospective”
- Sally Beauty Holdings for “Sally Beauty and CosmoProf Engagement and Opt-in Growth”
Value Impact: Brands that excel in driving revenue and creating valuable app or website customer experiences.
- CIMB Group for “Empowering Simplicity with CIMB Clicks”
- Boots for “Celebrating 25 Years of the Boots Meal Deal with a Gamified Experience and Enhanced Digital Offers”
- Alaska Airlines for “Unlocking Guest Value and Revenue in the Mobile App”
Unified Experience: Brands that achieve exceptional customer engagement from cohesive, contextually connected experiences wherever customers choose to interact.
- Access Bank for “Connect and Convert: Targeted Push Communication”
- Asda for “Multichannel Rewards Round-Up”
- Synchrony Financial for “CareCredit Year in Review”
The 2024 Altitude Awards are judged by an esteemed panel of industry experts who score each entry on overall performance, amplification, innovation and degree of difficulty. 2024 Altitude Award judges include: Pietro Lambert, VP of Product Management at OneFootball; Lauren Hensley, Director of Mobile App Marketing and Lifecycle at VML; Tom Burrell, independent retention marketing consultant formerly with DAZN; and Di Wu, VP of Audience Engagement and Lifecycle Marketing at Pandora.
The winners of the 2024 Altitude Awards will be announced during a ceremony at Airship’s Mobile Leaders Forum Berlin on November 14. Mobile Leaders Forum Berlin brings together mobile experience leaders for discussions on the challenges, trends and opportunities impacting the industry. To join Airship at the event, RSVP at https://www.airship.com/events/mobile-leaders-forum-berlin-2024/. You can also watch the livestream for the awards ceremony at https://www.airship.com/events/join-the-altitude-awards-2024-ceremony-livestream/.
About Airship
Airship helps brands master mobile-first customer experiences to build lasting relationships and accelerate business growth.
Since 2009, Airship has enabled thousands of the world’s leading brands to be at the forefront of the customer experience revolution with industry-first support for push notifications, in-app messages and mobile wallet boarding passes — all now the norm in elevating experiences everywhere.
Today, the Airship Experience Platform provides an end-to-end solution for unifying experiences across apps, websites and all channels, including email, SMS, mobile wallet and more. Its no-code Experience Editor and Journeys AI solutions enable marketers and product managers to get work done in minutes instead of months, capturing more value across the entire customer lifecycle without ongoing developer support.
With the Airship Experience Platform and App Store Optimization technology and expertise, brands now have a complete set of solutions to optimize the entire customer lifecycle – from the point of discovery to loyalty – driving greater value for everyone involved.
For more information, visit www.airship.com, read our blog or follow us on X (formerly Twitter), LinkedIn and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030257413/en/
Contacts
Media Contact
North America:
Deidre Wright
Airship
+1 415-223-0832
deidre.wright@airship.com
Kali Myrick
Kali Myrick Communications
+1 503-580-4645
kali@kalimyrick.com
EMEA:
Ana Williams
Airship
+44 (0)20 3405 5160
press@airship.com
Pauline Delorme
Tyto PR
+44 (0)20 3934 8882
Airship@tytopr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom